scholarly journals APOLIPOPROTEIN B/A1 IS INDEPENDENTLY ASSOCIATED WITH CAROTID INTIMAL-MEDIAL THICKNESS IN CHRONIC KIDNEY DISEASE PATIENTS.

2012 ◽  
Vol 31 (2) ◽  
pp. A46
Author(s):  
Il Young Ki ◽  
m ◽  
Soo Bong Lee ◽  
Dong Won Lee ◽  
In Hye Hwang ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Apolipoprotein B ◽  
Intimal Medial Thickness ◽  
Carotid Intimal Medial Thickness

PW195 Lipid profile and Carotid Intimal Medial thickness in different stages of Chronic Kidney Disease

Global Heart ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e297 ◽  
Author(s):  
Avinash K. Dubey ◽  
Yogesh Varma ◽  
Sonika dubey ◽  
Gurmeet Singh ◽  
Abhishek K. Dubey ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Lipid Profile ◽  
Intimal Medial Thickness ◽  
Carotid Intimal Medial Thickness

scholarly journals Effect of statins on atherosclerosis in chronic kidney disease patients guided by CD4+CD28nullT cells over duration of six months

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
A M Okba ◽  
H S Abdelawi ◽  
R Y Shaheen ◽  
M N Amin ◽  
M M Amin ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
T Cells ◽  
Kidney Disease ◽  
Statin Therapy ◽  
Inflammatory Process ◽  
Chronic Renal Disease ◽  
P Value ◽  
Carotid Intimal Medial Thickness ◽  
Group A ◽  
Multivariable Regression

Abstract Objectives Chronic kidney disease and atherosclerosis are considered to be inflammatory process in which T cells and cytokines participate. This study determines the effect of statin therapy as an anti-inflammatory agent on the level of CD4+CD28null T lymphocyte population, and subsequently on atherosclerosis in patients with chronic renal disease. Methods We recruited 90 chronic kidney disease patients. The patients were divided into three groups according to carotid intimal medial thickness (CIMT) as an indicator of atherosclerosis. Two groups (group A in whom CIMT above 0.95 mm and B in whom CIMT below 0.95 mm) were given statin (atorvastatin 20mg) while the third group (group C in whom CIMT below 0.95 mm) continue only on the conservative treatment for CKD patients. CD4+CD28null T cells was measured in the three groups at the beginning of the study and after 6 months of statin therapy. Results CD4+CD28null T cells was decreased in statin groups (group A and B) when compared to no-statin group (group C) at the end of the study. Multivariable regression analysis for the effect of statin therapy showed that statin can independently increase the percentage of decrease both CD4+CD28null cells at the end of our study (p-value <0.0001). Conclusion Our study demonstrates that statins reduce CD4+CD28null T cells in CKD patients especially with atherosclerosis suggesting that statins may help in altering the inflammatory process that lead to atherosclerosis.

scholarly journals Serum Lipoprotein(a) Level and Apolipoprotein B/A1 Ratio in Patients of Hemodialysis and Peritoneal Dialysis: A New Approach to Predict Cardiovascular Risks in Chronic Kidney Disease

2020 ◽  
Vol 8 (2) ◽  
pp. 91-95
Author(s):  
Salahuddin Feroz ◽  
Abu Zafor Md Salahuddin ◽  
Md Al Rizwan Russel ◽  
Rafi Nazrul Islam ◽  
Miliva Mozaffor ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Peritoneal Dialysis ◽  
Kidney Disease ◽  
Apolipoprotein B ◽  
Serum Lipoprotein ◽  
Dialysis Adequacy ◽  
Lipoprotein A ◽  
Ckd Stage ◽  
Group A ◽  
Group B

Background: Serum lipoprotein(a) and Apolipoprotein B/A1 ratio are new, independent cardiovascular risk factors in patients on dialysis. Conversely, the choice of dialysis procedure influences the uremic dyslipidemia in chronic kidney disease (CKD) patients. Objective: To compare lipoprotein(a) levels and apolipoprotein B/A1 ratio in patients of chronic kidney disease (CKD) stage 5 undergoing hemodialysis or peritoneal dialysis. Methods: This cross-sectional study was conducted in Department of Nephrology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh, from September 2016 to March 2018. A total of 55 CKD stage 5 patients were included in the study – 31 in hemodialysis (HD) (group A) and 24 in continuous ambulatory peritoneal dialysis (CAPD) (group B). Group A patients were on low flux dialysis with bicarbonate dialysate 4 hours twice weekly dialysis with unfractionated heparin as anti-coagulant with a dialysis adequacy (Kt/V) >1.2. Group B patients were on 3 exchanges over 24 hours with 2 litres of 1.5% glucose fluid with a weekly measured Kt/V >1.7. Serum levels of Lipoprotein(a), Apolipoprotein B/A1 ratio were measured in both groups by using the standard laboratory technique. Results: In group A, most of the patients were in 31-50 years age group (45.1%), while in group B, majority belonged to >50 years age group (54.16%). Patients’ gender showed a male predominance in both groups, i.e. 54.83% and 70.83% respectively. Most of the patients were from urban areas, i.e. 87.1% and 70.8% group A and B respectively. Dialysis adequacy (Kt/V) was found 1.46 for HD patients (group A) and 1.81 for CAPD patients (group B). Dyslipidemia was evident more in CAPD patients than HD patients, as per raised serum Lipoprotein(a) level (83.3% vs 74.1%) and raised Apolipoprotein B/A1 ratio (100% vs. 77.4%). Moreover, comparing with HD patients, CAPD patients showed increased level of serum Lipoprotein(a) (41.4±23.5 mg/dl vs 37.4±25.3 mg/dl; p>0.05) and Apolipoprotein B/A1 ratio (1.59±0.24 vs 1.04±0.22; p<0.001). Conclusion: The maintenance CAPD treatment is associated with more pronounced alterations of the lipoproteins and lipid metabolism than those observed during HD treatment. Besides, serum lipoprotein(a) level and apolipoprotein B/A1 ratio were found simple, accessible and effective markers of dyslipidemia in both groups. Bangladesh Crit Care J September 2020; 8(2): 91-95

Sign in / Sign up

Export Citation Format

Share Document